De Novo Pharmaceuticals
De Novo signs first academic licence with the University of Hertfordshire
1st September 2011
‘Having used SkelGen previously, I know what a fantastic ideas generator it is for drug discovery. It will be a great asset for our research projects’, said Dr Stewart Kirton, Senior Lecturer in Pharmaceutical Chemistry. Bill Harris, for De Novo, says ‘This is an important step towards De Novo’s goal to broaden access to SkelGen throughout the computational and medicinal chemistry community.’

Print this page



 
Recent News
De Novo Agrees Med Chem Synthesis Deal
De Novo Launches Academic Access Programme
De Novo Takes SkelGen to Japan
De Novo Launches ‘Stand-Alone; SkelGen
De Novo signs first academic licence with the University of Hertfordshire
De Novo Pharmaceuticals announces a Drug Discovery Partnership agreement with Achaogen
De Novo Pharmaceuticals Ltd. Announces New Partnering Opportunity in Diabetes
De Novo Pharmaceuticals Ltd. Announces New Therapeutic Focus In the Area Of Metabolic Diseases And Appoints New Scientific Advisory Board.
De Novo Pharmaceuticals Ltd Announces Drug Discovery Collaboration Agreement with Genzyme
De Novo launches Reflex, a major upgrade to its in silico drug design platform
© 2007 De Novo Pharmaceuticals
Developed by Northbank Communications Ltd. Support Services by Secured IT Ltd